Bionoia Where life meets thought
Back to Journal
Journal Microbiome ecology
Discovery

Letter to the Editor: Gut microbiota–bile acid crosstalk - Prevotellaceae NK3B31 and 7-ketolithocholic acid drive metabolic benefits of distal bowel resection with preservation of terminal ileum

Hypothesis
Read original paper
Editor's note
Gut bacteria shape glucose metabolism after bowel surgery through a specific bile acid they produce—a mechanistic link that moves beyond observing dysbiosis to explaining *how* microbial shifts drive metabolic benefit. This taxon-specific finding occupies emerging ground between descriptive ecology and actionable biology, opening rational targets for mimicry via probiotics or synthetic analogs. Bariatric surgeons, metabolic hepatologists, and researchers studying FXR signaling should engage with this axis as a prototype for microbiota-directed therapeutics.

Source: openalex · Xu Cui, Long-Yao Xu, Bing-Qian Yin, liu chen, Zheng Liang · World Journal of Hepatology · 2026-05-26

URL: https://doi.org/10.4254/wjh.v18.i5.115514

AI rationale (4/5, tier: emerging): Taxon-specific dysbiosis mechanism (Prevotellaceae) linked to metabolic phenotype via bile acid axis; mechanistic depth beyond descriptive ecology.


This letter commends on the study published in World Journal of Gastroenterology by Xu et al , which elucidated the mechanism by which distal bowel resection with terminal ileum preservation (DBRPI) improves hepatic gluconeogenesis via the Prevotellaceae NK3B31_group /7-ketolithocholic acid (7-KLCA)/farnesoid X receptor (FXR) axis. Using multiomics and functional assays, Xu et al identified this microbial–bile acid (BA) axis as central to the metabolic benefits of DBRPI, linking microbial enrichment (e.g. , Prevotellaceae NK3B31_group ) to increased 7-KLCA levels and FXR activation, thereby suppressing gluconeogenic gene expression. We highlight the novelty of this work in its focus on taxon-specific microbial and BA dynamics, which advances the understanding of postoperative glucose regulation. Additionally, we note its translational potential—targeting this axis via probiotics or 7-KLCA analogs—and raise several open questions, including causal validation of the microbial taxon, serum 7-KLCA dynamics, and glucagon-like-peptide-1/FXR interplay. Overall, this study bridges gut microbiota and BA crosstalk, offering actionable insights for the treatment of metabolic disease.

Published 2026-05-28 · Last kit-update 2026-05-28